Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis

被引:134
作者
Rao, Archana S.
Wong, Banny S.
Camilleri, Michael
Odunsi-Shiyanbade, Suwebatu T.
McKinzie, Sanna
Ryks, Michael
Burton, Duane
Carlson, Paula
Lamsam, Jesse [1 ]
Singh, Ravinder [1 ]
Zinsmeister, Alan R. [2 ]
机构
[1] Mayo Clin, Coll Med, Div Biomed Stat & Informat, Immunochem Core Lab, Rochester, MN USA
[2] Mayo Clin, Coll Med, Div Biomed Stat & Informat, Dept Hlth Sci Res, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
Bile Acid; 7 alpha C4; FGF19; FGFR4; BILE-ACID MALABSORPTION; PERFORMANCE-CHARACTERISTICS; FUNCTIONAL CONSTIPATION; RABBIT COLON; TRANSIT; SECRETION; 7-ALPHA-HYDROXY-4-CHOLESTEN-3-ONE; PERMEABILITY; STIMULATION; METABOLISM;
D O I
10.1053/j.gastro.2010.07.052
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Sodium chenodeoxycholate (CDC) accelerates colonic transit in health. Our aim was to examine pharmacodynamics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C). METHODS: In a double-blind placebo-controlled study, 36 female patients with IBS-C were randomized to treatment with delayed-release oral formulations of placebo, 500 mg CDC, or 1000 mg CDC for 4 days. We assessed gastrointestinal and colonic transit, stool characteristics, and associations of transit with fasting serum 7 alpha C4 (surrogate of bile acid synthesis) and FGF19 (negative regulator of bile acid synthesis) levels. Candidate genetic polymorphisms involved in regulation of bile acid synthesis were analyzed in the 36 patients with IBS-C and 57 healthy volunteers to assess genetic influence on effects of CDC on transit. RESULTS: Overall colonic transit and ascending colon emptying (AC t(1/2)) were significantly accelerated in the CDC group compared with placebo (P = .005 and P = .028, respectively). Looser stool consistency (P = .003), increased stool frequency (P = .018), and greater ease of passage (P = .024) were noted with CDC compared with placebo. The most common side effect was lower abdominal cramping/pain (P = .01). Fasting serum 7 alpha C4 (but not FGF19) was positively associated with colonic transit (r(s) = 0.749, P = .003, placebo group). Genetic variation in FGFR4 was associated with AC t(1/2) in response to CDC (uncorrected P = .015); alpha Klotho beta variant showed a gene-by-treatment interaction based on patient subgroup (uncorrected P = .0088). CONCLUSIONS: CDC accelerates colonic transit and improves bowel function in female patients with IBS-C. The rate of bile acid synthesis influences colonic transit. Genetic variation in negative feedback inhibition of bile acid synthesis may affect CDC-mediated acceleration of colonic transit.
引用
收藏
页码:1549 / +
页数:11
相关论文
共 34 条
[1]   Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation [J].
Abrahamsson, Hasse ;
Ostlund-Lindqvist, Ann-Margret ;
Nilsson, Ralf ;
Simren, Magnus ;
Gillberg, Per-Goran .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2008, 43 (12) :1483-1488
[2]   Taurodeoxycholate modulates apical Cl-/OH- exchange activity in Caco2 cells [J].
Alrefai, Waddah A. ;
Saksena, Seema ;
Tyagi, Sangeeta ;
Gill, Ravinder K. ;
Ramaswamy, Krishnamurthy ;
Dudeja, Pradeep K. .
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (05) :1270-1278
[3]   Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome [J].
Andresen, Viola ;
Camilleri, Michael ;
Busciglio, Irene A. ;
Grudell, April ;
Burton, Duane ;
Mckinzie, Sanna ;
Foxx-Orenstein, Amy ;
Kurtz, Caroline B. ;
Sharma, Vineeta ;
Johnston, Jeffrey M. ;
Currie, Mark G. ;
Zinsmeister, Alan R. .
GASTROENTEROLOGY, 2007, 133 (03) :761-768
[4]   The proximal colonic motor response to rectal mechanical and chemical stimulation [J].
Bampton, PA ;
Dinning, PG ;
Kennedy, ML ;
Lubowski, DZ ;
Cook, IJ .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2002, 282 (03) :G443-G449
[5]   TREATMENT OF CONSTIPATION WITH CHENODEOXYCHOLIC ACID [J].
BAZZOLI, F ;
MALAVOLTI, M ;
PETRONELLI, A ;
BARBARA, L ;
RODA, E .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1983, 11 (02) :120-123
[6]   Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: Five-year posttrial follow-up report from the POSCH [J].
Buchwald, H ;
Varco, RL ;
Boen, JR ;
Wiliams, SE ;
Hansen, BJ ;
Campos, CT ;
Campbell, GS ;
Pearce, MB ;
Yellin, AE ;
Edmiston, WA ;
Smink, RD ;
Sawin, HS .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (11) :1253-1261
[7]   Pathophysiology as a basis for understanding symptom complexes and therapeutic targets [J].
Camilleri, M ;
Talley, NJ .
NEUROGASTROENTEROLOGY AND MOTILITY, 2004, 16 (02) :135-142
[8]   Measurement of serum 7α-hydroxy-4-cholesten-3-one (or 7αC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry [J].
Camilleri, M. ;
Nadeau, A. ;
Tremaine, W. J. ;
Lamsam, J. ;
Burton, D. ;
Odunsi, S. ;
Sweetser, S. ;
Singh, R. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2009, 21 (07) :734-E43
[9]   DOSE-RELATED EFFECTS OF CHENODEOXYCHOLIC ACID IN THE RABBIT COLON [J].
CAMILLERI, M ;
MURPHY, R ;
CHADWICK, VS .
DIGESTIVE DISEASES AND SCIENCES, 1980, 25 (06) :433-438
[10]   EFFECTS OF CHENODEOXYCHOLIC AND URSODEOXYCHOLIC ACID ON ABSORPTION, SECRETION AND PERMEABILITY IN RAT COLON AND SMALL-INTESTINE [J].
CASPARY, WF ;
MEYNE, K .
DIGESTION, 1980, 20 (03) :168-174